Search results
Results From The WOW.Com Content Network
Pegylated interferon alfa-2a, sold under the brand name Pegasys among others, is medication used to treat hepatitis C and hepatitis B. [3] For hepatitis C it is typically used together with ribavirin and cure rates are between 24 and 92%. [3] [4] For hepatitis B it may be used alone. [5] It is given by injection under the skin. [3] Side effects ...
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery. [3] Also used to treat hepatitis C (typically, in combination with ribavarin), it is no longer recommended due to poor efficacy and adverse side-effects. [4] Subcutaneous injection is the preferred delivery method. [3]
One was first approved for medical use in 1986. [59] For example, in January 2001, the Food and Drug Administration (FDA) approved the use of PEGylated interferon-alpha in the USA; in this formulation, PEGylated interferon-alpha-2b ( Pegintron ), polyethylene glycol is linked to the interferon molecule to make the interferon last longer in the ...
Peginterferon-alfa may refer to: Peginterferon alfa-2a, an antiviral drug used in treatment for hepatitis C and hepatitis B; Peginterferon alfa-2b, a treatment for ...
Peginterferon beta-1a, sold under the brand name Plegridy, is medication used to treat multiple sclerosis. [4] [5]The most common side effects include headache, muscle pain, joint pain, influenza (flu)-like symptoms, pyrexia (fever), chills, asthenia (weakness), and erythema (reddening of the skin), pain or pruritus (itching) at the injection site.
Women report adverse events from approved medicines 52% more often than men–and serious ones, including fatalities, 36% more often, according to the U.S. Food and Drug Administration. In ...
This page was last edited on 26 June 2016, at 20:17 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may ...
Interferon alfa-2b is an antiviral or antineoplastic drug. It is a recombinant form of the protein Interferon alpha-2 that was originally sequenced and produced recombinantly in E. coli [1] in the laboratory of Charles Weissmann at the University of Zurich, in 1980.